Amir Cohen, MD
Ophthalmology · New Haven, CTNPI 1841487220
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $171,408 of the $265,678 with a category attached, or 64.5%. 21 manufacturers reported payments, led by AbbVie at 40.0% of the total. Reporting peaked in 2022 at $86,220 and has fallen 57.9% since, to $36,280 in 2025. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 708 payments — averaging $375.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$106K
- Sight Sciences, Inc.$87K
- Bausch & Lomb Americas Inc.$44K
- Aerie Pharmaceuticals, Inc.$13K
- Glaukos Corporation$12K
- Alcon$2K
- plus $2K from 15 others
Across 14 payments — averaging $12,515 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$175K
What the payments were for
- Consulting fees$65,83225%
- Speaking & faculty fees$171,40865%
- Travel & lodging$4,9162%
- Food & beverage$23,5029%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 331 | $106,255 |
| Sight Sciences, Inc. | 113 | $86,544 |
| Bausch & Lomb Americas Inc. | 78 | $44,052 |
| Aerie Pharmaceuticals, Inc. | 27 | $12,741 |
| Glaukos Corporation | 24 | $11,845 |
| Alcon | 37 | $2,077 |
| NEW World Medical,inc. | 14 | $420 |
| Ocular Therapeutix, Inc. | 23 | $417 |
| Biotissue Holdings Inc. | 14 | $359 |
| Astellas Pharma US Inc | 17 | $350 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $170 |
| Thea Pharma Inc. | 9 | $169 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $130 |
| Novartis | 3 | $41 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Dompe US, Inc. | 1 | $15 |
| Omeros Corporation | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$94,844
- OMNI(R) SURGICAL SYSTEM (US)$61,962
- OMNI$23,654
- SION SURGICAL INSTRUMENT$20,956
- enVista MX60 IOL$17,123
- Rhopressa$12,375
- Rocklatan$12,375
- iStent inject W$8,167
- XEN GLAUCOMA TREATMENT SYSTEM$5,283
- iStent inject Trabecular Micro-Bypass Stent System$3,223
- LenSx$1,140
- IC-8 Apthera IOL$972
- STELLARIS ELITE$972
- XEN$690
- IACCESS$277
- iDose$182
- Clareon$170
- Izervay$125
- ENVISTA ENVY IOL$124
- LUMIGAN$122
How this compares
$265,678 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 211 | $103,707 |
| RhopressaNetarsudil Mesylate | 170 | $81,506 |
| CombiganBrimonidine Tartrate/Timolol | 92 | $39,579 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $31,238 |
| RestasisCyclosporine | 17 | $22,081 |
| VyzultaLatanoprostene Bunod | 25 | $21,198 |
| Prednisolone Acetate | 525 | $20,769 |
| Brinzolamide | 90 | $18,173 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 85 | $17,292 |
| Alphagan PBrimonidine Tartrate | 35 | $16,832 |
| Brimonidine Tartrate | 206 | $16,284 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 66 | $14,752 |
| Latanoprost | 763 | $10,747 |
| Dorzolamide Hcl | 503 | $9,996 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 45 | $9,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $106,255 | $182,198355 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $12,741 | $112,743237 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $44,052 | $21,19825 claims |
| AlconSimbrinza | $2,077 | $17,29285 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $170 | $2,17612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in New Haven
- Paul KangNew Haven$40K
- Brian HaflerNew Haven$15K
- James WeiszNew Haven$14K
- Kristen NwanyanwuNew Haven$12K
- Lucian del PrioreNew Haven$9K
- Gargi VoraNew Haven$7K
- James TsaiNew Haven$7K
- Wayne LarrisonNew Haven$5K
- Sara NetterNew Haven$3K
- John HuangHartford$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.